6a7b
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==AKR1C3 complexed with new inhibitor with novel scaffold== | |
| - | + | <StructureSection load='6a7b' size='340' side='right'caption='[[6a7b]], [[Resolution|resolution]] 2.37Å' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[6a7b]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6A7B OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6A7B FirstGlance]. <br> | |
| - | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=9S0:(4R)-6-amino-4-(4-hydroxy-3-methoxy-5-nitrophenyl)-3-propyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile'>9S0</scene>, <scene name='pdbligand=DMF:DIMETHYLFORMAMIDE'>DMF</scene>, <scene name='pdbligand=NAP:NADP+NICOTINAMIDE-ADENINE-DINUCLEOTIDE+PHOSPHATE'>NAP</scene></td></tr> | |
| - | [[Category: | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6a7b FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6a7b OCA], [http://pdbe.org/6a7b PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6a7b RCSB], [http://www.ebi.ac.uk/pdbsum/6a7b PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6a7b ProSAT]</span></td></tr> |
| + | </table> | ||
| + | == Function == | ||
| + | [[http://www.uniprot.org/uniprot/AK1C3_HUMAN AK1C3_HUMAN]] Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta-PGF2 to PGD2. Functions as a bi-directional 3-alpha-, 17-beta- and 20-alpha HSD. Can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites. Preferentially transforms androstenedione (4-dione) to testosterone. | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Chen, Y]] | ||
[[Category: Zhang, H]] | [[Category: Zhang, H]] | ||
[[Category: Zhao, Y]] | [[Category: Zhao, Y]] | ||
| - | [[Category: Chen, Y]] | ||
[[Category: Zheng, X]] | [[Category: Zheng, X]] | ||
| + | [[Category: Aldo-keto reductase family 1 member c3]] | ||
| + | [[Category: Oxidoreductase]] | ||
| + | [[Category: Prostaglandin f synthase]] | ||
| + | [[Category: Type 5 17-beta-hydroxysteroid dehydrogenase]] | ||
Revision as of 05:44, 3 July 2019
AKR1C3 complexed with new inhibitor with novel scaffold
| |||||||||||
